Search
Dexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Hypercholesterolemia, Autosomal Dominant
go.drugbank.com/conditions/DBCOND0037437Synonyms: LDL receptor disorder, LDL - Low density lipoprotein receptor disorderDarunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigational[L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. … [L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection.
Categories: Antivirals used in combination for the treatment of HIV infectionsFlurandrenolide
go.drugbank.com/drugs/DB00846ApprovedA corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive.
Categories: Corticosteroid Hormone Receptor AgonistsCrofelemer
go.drugbank.com/drugs/DB04941ApprovedInvestigationalCrofelemer, previously known as the investigational drug SP-303, is a novel proanthocyanidin purified from the bark latex of the Amazonian Croton tree <i>Croton lechleri</i>. … It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.
Categories: Compounds used in a research, industrial, or household settingCX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Nabumetone
go.drugbank.com/drugs/DB00461Approved[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].
Basiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalA recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking AntibodyIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. … Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.
Categories: Adenosine A2 Receptor Antagonists, Purinergic P1 Receptor AntagonistsEfmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIt is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. … The B domain of factor VIII is deleted. In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551].